Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
What is the importance of difference in LCM strategy in drug development? – Learnings from Keytruda and Opdivo
Ist Teil von
Drug discovery today, 2022-12, Vol.27 (12), p.103390-103390, Article 103390
Ort / Verlag
England: Elsevier Ltd
Erscheinungsjahr
2022
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
•Despite the fact that Opdivo was approved first by a smaller margin, global sales of Keytruda in 2020 were almost double dose of Opdivo.•Although two this preparations differ in their epitopes, their physical and biological properties are nearly equivalent.•Publicly available data suggested that the cause of the difference in sales is the supplier's business strategy.
Immune checkpoint inhibitors have changed how cancer is treated. As of February 2022, six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the differences in commercial success between Keytruda and Opdivo is reviewed by analyzing inter-organizational deals since their launch in 2014. Both showed a correlation between the cumulative number of indications and product sales trends, the latter crossing from 2017 to 2018. Differences in sales were due to different approaches to life cycle management by inter-organizational deals and drug development strategies, the key to commercial success.